BioDelivery Sciences International, Inc. (NASDAQ:BDSI)
BioDelivery Sciences International, Inc. (NASDAQ:BDSI) is set to announce financial results for the first three months of the year on May 15, 2017. The company is fresh from filing Form 12b-25 with the U.S Securities and Exchange Commission in which it asked for five extra days for the completion of an audit report with regards to termination of its license report with Endo.
Sales Channel Restructuring
When the biopharmaceutical reports its financial results, at stake will be the performance of its key product Belbuca for the treatment of back pain. Sales for the opioid dependence treatment Bunavail have been lackluster in the recent past and it will interesting to see if they improved in Q1 2017.
BioDelivery Sciences International, Inc. (NASDAQ:BDSI) has been working behind the scenes as it looks to improve sales for its key products. Reduction of sales force has already come into focus, the company has reduced the number of sales territories in which it operates.
However, the company has sought to focus on growth-oriented territories even with the restructuring push. BioDelivery has also sought to secure new managed care contacts on either an exclusive or preferred status. The company has started running a direct-to-patient digital advertising campaign in four cities as it looks to accelerate sales growth.
BioDelivery Sciences International, Inc. (NASDAQ:BDSI) expects Bunavail to generate a substantial amount of profit going forward given the reduced cost structure in place as well as growth opportunities at stake. The Food and Drug’s Administration recently approved the drug’s usage as a buprenorphine treatment for opioid dependence.
“The approval broadens the indication for BUNAVAIL to include induction, or the initial process undertaken when a patient is transitioned from the abused opioid responsible for their addiction to the dose of BUNAVAIL which is intended to provide relief from cravings and withdrawal. Induction is the first step to assist a patient in discontinuing or markedly reducing their use of other opioids,” said the company in a press release.
The expansion should go a long way in making Bunavail highly competitive in the market giving sales representatives the much-needed leverage for communicating its benefits in the treatment of Opioid dependence.
BioDelivery Sciences International, Inc. (NASDAQ:BDSI) has underperformed the market over the past 12 months having risen by 2.8% compared to the industry average of 3.9%. Missing earnings estimates in two of the last four quarters have not helped the stock’s sentiments among investors. However, the company beating consensus estimates with the upcoming earnings report could help bolster investor sentiment.
BioDelivery Sciences International, Inc. (NASDAQ:BDSI) stock was unchanged in Friday trading session ending the week at $1.90 a share.
I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.
About the author: Monica Gray has an undergraduate degree in Accounting and an MBA – earned with Honors. She has six years of experience in the financial markets and has been a securities analyst for the past two years.